Recombinant Mayaro Virus E2 Envelope Protein, His-tagged
Specification
Related Products
| Cat#: |
MAY-490 |
| Product Name: |
Recombinant Mayaro Virus E2 Envelope Protein, His-tagged |
| Description: |
Mayaro Virus E2 protein is a unique product that has been developed in response to the need for high purity, properly assembled and glycosylated Mayaro virus antigens for use in the development of Mayaro virus diagnostics and in vaccine development and research / development. Mayaro Virus E2 protein is produced in human cell lines using state-of-the-art expression techniques. The protein is produced from amino-acids 328-691 of the Mayaro structural polyprotein, and incorporates a C-terminal 6x HIS tag. We also offer alternative versions with mouse or human Fc tags to offer researchers maximum flexibility in their choice of reagent. |
| Gene: |
E2 Envelope |
| Species: |
MAYV |
| Synonyms: |
Mayaro Virus E2 Envelope |
| Formulation: |
DPBS pH 7.4, sterile filtered |
| Concentration: |
0.16 mg/mL |
| Purity: |
Greater than 90% purity by SDS-PAGE. |
| Storage: |
Short Term Storage: +2 centigrade to +8 centigrade
Long Term Storage: -80 centigrade |
| Notes: |
This product is intended for research and manufacturing uses only. It is not a diagnostic device. The user assumes all responsibility for care, custody and control of the material, including its disposal, in accordance with all regulations. |
| Tags: |
C-terminal His |
| Freezing: |
Can be frozen, but avoid multiple freeze/thaw cycles. |
| Sequence Strain: |
Acre27(GenBank accession number KM400591.1) |
| Background: |
Mayaro virus (MAYV) is a positive-sense single stranded RNA virus that belongs to the genus Alphavirus, a member of the Togaviridae family of viruses. It is a member of the Semliki Forest antigenic sero-complex, a serological group within the Alphavirus genus, and is closely related to Chikungunya virus (CHIKV) (Esposito, D.L.A).
MAYV is recognised as an emerging virus with the potential to cause a major epidemic in Central and South American countries. Currently, there is no licensed prophylactic vaccine or specific treatment for MAYV fever. Prevention of MAYV is through vector control measures to reduce transmission of the virus. Given the geographical distribution of MAYV and the similarity of the symptoms of Mayaro fever to infections caused by other arboviruses such Dengue fever, Chikungunya and Zika virus, it is considered important to be able to differentiate diagnostically between these arboviral diseases (CDC). Diagnosis of MAYV infection may be achieved by serological testing for MAYV specific IgM antibodies using enzyme immunoassays (EIA). However, cross reactivity with related viruses can reduce assay sensitivity and prevent accurate diagnosis (Figueiredo, ML). |
For research or industrial raw materials, not for personal medical use!
